ZA200103252B - A method of affinity separation and ligands for use therein. - Google Patents
A method of affinity separation and ligands for use therein. Download PDFInfo
- Publication number
- ZA200103252B ZA200103252B ZA200103252A ZA200103252A ZA200103252B ZA 200103252 B ZA200103252 B ZA 200103252B ZA 200103252 A ZA200103252 A ZA 200103252A ZA 200103252 A ZA200103252 A ZA 200103252A ZA 200103252 B ZA200103252 B ZA 200103252B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- affinity
- residues
- asn
- binding
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000000926 separation method Methods 0.000 title claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 157
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 148
- 235000018102 proteins Nutrition 0.000 claims abstract description 141
- 238000009739 binding Methods 0.000 claims abstract description 52
- 230000027455 binding Effects 0.000 claims abstract description 50
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 15
- 230000004048 modification Effects 0.000 claims abstract description 13
- 238000012986 modification Methods 0.000 claims abstract description 13
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000009582 asparagine Nutrition 0.000 claims abstract description 8
- 229960001230 asparagine Drugs 0.000 claims abstract description 8
- 235000001014 amino acid Nutrition 0.000 claims description 35
- 229940024606 amino acid Drugs 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 17
- 238000001042 affinity chromatography Methods 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 230000009870 specific binding Effects 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 108010088160 Staphylococcal Protein A Proteins 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002823 phage display Methods 0.000 claims description 4
- 230000003019 stabilising effect Effects 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 101710096438 DNA-binding protein Proteins 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 102100027211 Albumin Human genes 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 32
- 108091006905 Human Serum Albumin Proteins 0.000 description 25
- 102000008100 Human Serum Albumin Human genes 0.000 description 25
- 238000002703 mutagenesis Methods 0.000 description 13
- 231100000350 mutagenesis Toxicity 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 239000012491 analyte Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000006240 deamidation Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000002708 random mutagenesis Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- -1 cyclic imide Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011012 sanitization Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003164 beta-aspartyl group Chemical group 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9823071.7A GB9823071D0 (en) | 1998-10-21 | 1998-10-21 | A method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200103252B true ZA200103252B (en) | 2002-07-22 |
Family
ID=10841043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200103252A ZA200103252B (en) | 1998-10-21 | 2001-04-20 | A method of affinity separation and ligands for use therein. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6831161B1 (fr) |
| EP (2) | EP1672068A1 (fr) |
| JP (1) | JP4801258B2 (fr) |
| AT (1) | ATE305970T1 (fr) |
| AU (1) | AU773368B2 (fr) |
| CA (2) | CA2347960C (fr) |
| DE (1) | DE69927598T2 (fr) |
| DK (1) | DK1123389T3 (fr) |
| GB (1) | GB9823071D0 (fr) |
| NO (1) | NO323994B1 (fr) |
| WO (1) | WO2000023580A1 (fr) |
| ZA (1) | ZA200103252B (fr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200943D0 (sv) * | 2002-03-25 | 2002-03-25 | Amersham Biosciences Ab | Mutant protein |
| US7709209B2 (en) | 2002-03-25 | 2010-05-04 | Ge Healthcare Bio-Sciences Ab | Protein ligands |
| GB0214007D0 (en) * | 2002-06-18 | 2002-07-31 | Common Services Agency | Removal of prion infectivity |
| AU2004245429A1 (en) * | 2003-06-10 | 2004-12-16 | Farallone Holding Bv | Binding peptides: methods for their generation and use |
| SE0301936D0 (sv) * | 2003-06-30 | 2003-06-30 | Affibody Ab | New polypeptide |
| WO2005003156A1 (fr) * | 2003-07-04 | 2005-01-13 | Affibody Ab | Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2) |
| US8642743B2 (en) | 2004-04-06 | 2014-02-04 | Affibody Ab | Method for reducing the immune response to a biologically active protein |
| CN101522278B (zh) | 2006-09-29 | 2016-08-10 | 通用电气健康护理生物科学股份公司 | 用于抗体分离的包含来自金黄色葡萄球菌a蛋白的结构域c的层析配体 |
| EP2190863B1 (fr) * | 2007-07-31 | 2015-09-02 | Affibody AB | Nouvelles compositions, nouveaux procédés et nouvelles utilisations |
| GB2452301A (en) | 2007-08-30 | 2009-03-04 | Ge Healthcare Bio Sciences Ab | Sterilization Method |
| US8592555B2 (en) * | 2008-08-11 | 2013-11-26 | Emd Millipore Corporation | Immunoglobulin-binding proteins with improved specificity |
| US8846877B2 (en) * | 2008-09-25 | 2014-09-30 | Jsr Corporation | Packing material for affinity chromatography |
| JP5229888B2 (ja) * | 2008-09-30 | 2013-07-03 | 独立行政法人産業技術総合研究所 | 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤 |
| SG195555A1 (en) | 2008-12-24 | 2013-12-30 | Emd Millipore Corp | Caustic stable chromatography ligands |
| EP2412809B1 (fr) | 2009-03-24 | 2017-08-09 | Kaneka Corporation | Protéine dotée d'une affinité pour l'immunoglobuline, et ligand d'affinité se liant à l'immunoglobuline |
| JP5952185B2 (ja) | 2010-03-24 | 2016-07-13 | 株式会社カネカ | 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド |
| CN103270044B (zh) | 2010-12-21 | 2016-03-09 | Jsr株式会社 | 亲和色谱用载体和分离免疫球蛋白的方法 |
| JP5997176B2 (ja) * | 2010-12-21 | 2016-09-28 | ザ ユニバーシティ オブ ウエスタン オンタリオＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｗｅｓｔｅｒｎ Ｏｎｔａｒｉｏ | プロテインａの新規アルカリ抵抗性変異体及びアフィニティークロマトグラフィーにおけるその使用 |
| JP6038774B2 (ja) | 2011-03-24 | 2016-12-07 | 株式会社カネカ | タンパク性物質結合性低分子化合物 |
| WO2012133342A1 (fr) | 2011-03-25 | 2012-10-04 | 株式会社カネカ | Nouveau polypeptide se liant à l'immunoglobuline |
| SG186552A1 (en) | 2011-06-08 | 2013-01-30 | Emd Millipore Corp | Chromatography matrices including novel staphylococcus aureus protein a based ligands |
| WO2014076177A1 (fr) * | 2012-11-14 | 2014-05-22 | Affibody Ab | Nouveau polypeptide |
| WO2014076179A1 (fr) | 2012-11-14 | 2014-05-22 | Affibody Ab | Nouveau polypeptide |
| US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
| CA2923133C (fr) | 2013-09-04 | 2019-05-28 | Emd Millipore Corporation | Procedes de nettoyage d'une colonne de chromatographie d'affinite fondee sur une proteine a |
| EP3459631A1 (fr) | 2013-09-27 | 2019-03-27 | Kaneka Corporation | Procédé de production de perles de cellulose poreuse utilisant une solution aqueuse alcaline et perles de cellulose poreuse produites selon ledit procédé |
| SG10201804200WA (en) | 2013-12-12 | 2018-07-30 | Emd Millipore Corp | Protein separations using an acrylamide containing filter |
| JP6369807B2 (ja) * | 2014-10-21 | 2018-08-08 | 株式会社プロテイン・エクスプレス | プロテインｌ変異体 |
| JPWO2016121701A1 (ja) | 2015-01-26 | 2017-11-09 | 株式会社カネカ | 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス |
| EP3252158A4 (fr) | 2015-01-26 | 2018-07-18 | Kaneka Corporation | Peptide de liaison de région variable de chaîne kappa d'immunoglobuline mutant |
| JP6705806B2 (ja) | 2015-03-26 | 2020-06-03 | Jsr株式会社 | イムノグロブリン結合タンパク質およびそれを用いたアフィニティー担体 |
| CN107969128A (zh) | 2015-04-17 | 2018-04-27 | 高山免疫科学股份有限公司 | 具有可调的亲和力的免疫调节蛋白 |
| CN108291220B (zh) | 2015-10-22 | 2022-10-28 | 普罗泰纳瓦株式会社 | 免疫球蛋白结合多肽 |
| WO2017191748A1 (fr) * | 2016-05-02 | 2017-11-09 | 株式会社カネカ | Peptide modifié de liaison à région variable de chaîne κ d'immunoglobuline |
| WO2017195638A1 (fr) | 2016-05-09 | 2017-11-16 | 株式会社カネカ | Procédé de purification d'un anticorps ou d'un fragment d'anticorps comportant une région variable de chaîne κ |
| WO2018162501A1 (fr) | 2017-03-07 | 2018-09-13 | Jmva Biotech Ab | Surfaces adsorbantes modifiées |
| EP3689894A4 (fr) | 2017-09-25 | 2021-12-22 | JSR Corporation | Protéine de liaison à l'immunoglobuline, et support d'affinité mettant en uvre celle-ci |
| EP3842536A4 (fr) | 2018-08-24 | 2023-01-18 | JSR Corporation | Protéine de liaison à l'immunoglobuline et support d'affinité l'utilisant |
| KR20230112616A (ko) | 2020-10-13 | 2023-07-27 | 아비타이드 엘엘씨 | 3중-나선 번들 단백질들의 친화성 리간드 라이브러리 및 이의 용도 |
| EP4269590A1 (fr) | 2020-12-22 | 2023-11-01 | Protenova Co., Ltd. | Polypeptide se liant aux immunoblobulines |
| CN117241866A (zh) | 2021-02-19 | 2023-12-15 | 艾维泰有限责任公司 | Aav2亲和剂 |
| GB2609185A (en) | 2021-05-24 | 2023-02-01 | Astrea Uk Services Ltd | Scaffold for isolation of a biomolecule |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8204810L (sv) * | 1982-08-23 | 1984-02-24 | Pharmacia Fine Chemicals Ab | Hybrid-dna-molekyl, transformerad mikroorganism och sett att framstella protein a |
| US5401832A (en) * | 1984-12-24 | 1995-03-28 | Merck & Co., Inc. | Brain derived and recombinant acidic fibroblast growth factor |
| US5089473A (en) * | 1988-08-29 | 1992-02-18 | Monsanto Company | Somatotropin variants and their use |
| EP0863210A3 (fr) * | 1991-07-25 | 1999-09-22 | Oriental Yeast Co., Ltd. | Protéine articielle se liant aux immunoglobulines |
| JP2584697B2 (ja) * | 1991-08-23 | 1997-02-26 | オリエンタル酵母工業株式会社 | ＩｇＧ精製用組換え型プロテインＡ |
| EP0565978B1 (fr) * | 1992-04-16 | 1997-06-18 | MERCK PATENT GmbH | Support activés, leur fabrication et utilisation |
| SE9400088D0 (sv) * | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5736499A (en) * | 1995-06-06 | 1998-04-07 | Genencor International, Inc. | Mutant A-amylase |
| SE9503925D0 (sv) * | 1995-11-07 | 1995-11-07 | Pharmacia Biotech Ab | Separationsmedium för IgG |
| WO1998040488A1 (fr) * | 1997-03-12 | 1998-09-17 | Smithkline Beecham Corporation | Anticorps monoclonaux humanises anti-alphabeta 3 |
-
1998
- 1998-10-21 GB GBGB9823071.7A patent/GB9823071D0/en not_active Ceased
-
1999
- 1999-10-21 JP JP2000577291A patent/JP4801258B2/ja not_active Expired - Lifetime
- 1999-10-21 WO PCT/GB1999/003484 patent/WO2000023580A1/fr active IP Right Grant
- 1999-10-21 DK DK99950942T patent/DK1123389T3/da active
- 1999-10-21 US US09/830,080 patent/US6831161B1/en not_active Expired - Lifetime
- 1999-10-21 EP EP05077192A patent/EP1672068A1/fr not_active Ceased
- 1999-10-21 AU AU63532/99A patent/AU773368B2/en not_active Expired
- 1999-10-21 CA CA002347960A patent/CA2347960C/fr not_active Expired - Lifetime
- 1999-10-21 DE DE69927598T patent/DE69927598T2/de not_active Expired - Lifetime
- 1999-10-21 AT AT99950942T patent/ATE305970T1/de not_active IP Right Cessation
- 1999-10-21 EP EP99950942A patent/EP1123389B1/fr not_active Expired - Lifetime
- 1999-10-21 CA CA2633345A patent/CA2633345C/fr not_active Expired - Lifetime
-
2001
- 2001-04-20 ZA ZA200103252A patent/ZA200103252B/en unknown
- 2001-04-20 NO NO20011969A patent/NO323994B1/no not_active IP Right Cessation
-
2004
- 2004-12-01 US US11/000,747 patent/US20050100970A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1123389B1 (fr) | 2005-10-05 |
| JP2002527107A (ja) | 2002-08-27 |
| US6831161B1 (en) | 2004-12-14 |
| NO20011969D0 (no) | 2001-04-20 |
| DE69927598D1 (de) | 2006-02-16 |
| ATE305970T1 (de) | 2005-10-15 |
| CA2347960A1 (fr) | 2000-04-27 |
| JP4801258B2 (ja) | 2011-10-26 |
| NO323994B1 (no) | 2007-07-30 |
| CA2633345C (fr) | 2013-02-26 |
| GB9823071D0 (en) | 1998-12-16 |
| NO20011969L (no) | 2001-06-19 |
| CA2347960C (fr) | 2008-08-05 |
| DE69927598T2 (de) | 2006-07-13 |
| AU773368B2 (en) | 2004-05-20 |
| EP1672068A1 (fr) | 2006-06-21 |
| AU6353299A (en) | 2000-05-08 |
| CA2633345A1 (fr) | 2000-04-27 |
| WO2000023580A1 (fr) | 2000-04-27 |
| US20050100970A1 (en) | 2005-05-12 |
| DK1123389T3 (da) | 2006-01-16 |
| EP1123389A1 (fr) | 2001-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1123389B1 (fr) | Procede de separation par affinite et ligands utilises dans ce procede | |
| KR102578256B1 (ko) | 친화성 크로마토그래피를 위한 알칼리 안정 fc-결합 단백질 | |
| AU2016293063B2 (en) | Novel immunoglobulin-binding proteins and their use in affinity purification | |
| EP2690173B1 (fr) | Protéine pour matrice de séparation par chromatographie d'affinité | |
| O'Neil et al. | Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library | |
| Bratkovič | Progress in phage display: evolution of the technique and its applications | |
| EP0904541B1 (fr) | PURIFICATION DE L'ACTIVATEUR TISSULAIRE DU PLASMINOGENE (tPA) | |
| EP2495254B1 (fr) | Nouvelles protéines se liant à des immunoglobulines dont la spécificité est améliorée | |
| EP1179014B1 (fr) | Derives du domaine z d'une proteine staphylococcique a (spa) ayant une interaction avec au moins un domaine du facteur viii humain | |
| CA2710140C (fr) | Banques de polypeptides presentant une structure predeterminee | |
| EP3521304B1 (fr) | Protéines de liaison fc avec la cystéine dans la région hélicoïdale c-terminale | |
| JP5951509B2 (ja) | 免疫グロブリンＧＦｃ領域結合ポリペプチド | |
| US20180215785A1 (en) | Method for purifying antibody-like protein | |
| CA2399809A1 (fr) | Domaine de proteines combinatoire | |
| KR20110003547A (ko) | 인위적인 단백질 스캐폴드 | |
| US20180170973A1 (en) | Immunoglobulin-binding modified protein | |
| US20180215795A1 (en) | ANTIBODY-BINDING PROTEIN HAVING REDUCED ANTIBODY-BINDING CAPACITY IN ACIDIC pH REGIONS | |
| US20180215836A1 (en) | Immunoglobulin-binding modified protein | |
| EP3546476A1 (fr) | Protéines de liaison fc avec la cystéine dans la région hélicoïdale c-terminale |